regulatoryhigh confidence

FDA Approves Pimicotinib (Pimjetmi) for Symptomatic Tenosynovial Giant Cell Tumor

|Cancer Breakthroughs

The FDA listed an approval on November 10, 2026 for pimicotinib (Pimjetmi) for symptomatic tenosynovial giant cell tumor (TGCT). Details beyond the FDA notification listing were not independently verified.

Media

FDA oncology approval notification
FDA oncology approval notification — U.S. FDA

Sources

View full Cancer Breakthroughs dashboard